April 19, 2023

The Consolidated Appropriations Act of 2023 that was signed into law on December 29, 2022, enacted important changes in the treatment of opioid use disorder (OUD), including:

• the elimination of Drug Enforcement Agency (DEA) X-waiver requirement to prescribe buprenorphine
• an increase in the number of days from 14 days to 45 days before which certain controlled medications, such as long-acting (XR) injectable buprenorphine, must be administered after the pharmacy has delivered the medication to the prescribing healthcare professional.

The Guidance on Long-Acting (XR) Buprenorphine Injection that was issued in May 2022 has been revised to reflect these changes.  The Guidance can be found at: https://oasas.ny.gov/oasas-xr-buprenorphine-guidance

Please share this email with staff who prescribe medications.

Questions about the Guidance can be sent to the Addiction Medicine Mailbox at AddictionMedicine@oasas.ny.gov

Communications Department

NYS Office of Addiction Services and Supports (OASAS)